Curiously, my husband is in Abbvie's Duodopa study and has been for 2+ years. With FDA approval right around the corner, it appears that their goal is making their statistics look good not only to the FDA, but Medicare and private insurance agencies. Patient care for their guinea pigs in not necessarily their first priority. As I understand it, and I could be completely wrong, in the Phase I clinical trial there were only 65 patients nationwide. I mean, how can you draw any conclusions from that small sampling of people?